Neovacs SA (FR:ALNEV) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neovacs SA, a French biotech firm focused on inflammatory and autoimmune diseases, has announced a capital reduction to offset losses by decreasing the nominal share value from 0.005 euro to 0.0005 euro. The company’s share capital now stands at 125,968.0985 euros, divided into 251,936,197 shares. Investors are cautioned about potential share dilution and capital loss due to the company’s dilutive financing operations.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.